Emerging antiangiogenic agents in lung cancer

Clinical Lung Cancer

Volumn 7, Issue 5, 2006, Pages 304-308

  Lee, David ^a   Heymach, John V ^b  

^a CIG Media Group   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AG 013736; Epidermal growth factor receptor; Raf kinase inhibitors; Sorafenib; Vascular endothelial growth factor Trap

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; AG 13736; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; ERLOTINIB; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN TRAP; VATALINIB; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; BINDING AFFINITY; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; FEASIBILITY STUDY; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; IC 50; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; OVERALL SURVIVAL; PAIN; PROTEIN FUNCTION; RASH; SHORT SURVEY; SKIN DISCOLORATION; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; LUNG TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745005282     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.010     Document Type: Review

References (26)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
2. Motzer RJ, Rini BI, Michaelson MD, et al. Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials. Eur J Cancer Suppl 2005; 3:227 (Abstract #797).
3. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94(suppl 1):S6 (Abstract #3).
4. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. J Clin Oncol 2005; 23(16 suppl):1090s (Abstract #1094).
5. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16:1391-1397.
6. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
7. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16:1688-1694.
8. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
9. Hariharan S. AG13736: phase I and II data. Presented at: 6th International Lung Cancer Congress (Workshop presentation); June 15-18, 2005; Kauai, HI.
10. Rosen O. AMG 706: an oral anti-angiogenic/antitumor multikinase inhibitor. Presented at: 6th International Lung Cancer Congress (Workshop presentation); June 15-18, 2005; Kauai, HI.
11. Herbst R, Kurzrock R, Parson M, et al. AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors. Paper presented at 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; September 28-October 1, 2004; Geneva, Switzerland.
12. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65:4389-4400.
13. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005; 23(16 suppl):192s (Abstract #3002).
14. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9:5465-5476.
15. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337.
16. Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005; 23:4162-4171.
17. Adjei AA. Targeting multiple signal transduction pathways in lung cancer. Clin Lung Cancer 2005; 7(suppl 1):S39-S44.
18. Herbst R, Johnson B, Rowbottom J, et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo-controlled phase II trial. Lung Cancer 2005; 49(suppl 2):S35 (Abstract #O-100).
19. Blumenschein G. Sorafenib and sunitinib in non-small-cell lung cancer. Paper presented an First Annual New York Lung Cancer Symposium; November 1, 2005; New York, NY.
20. Blumenschein GR, Gatzemeier U, Fossella F, et al. A phase II multicenter uncontrolled trial of single agent sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced non-small-cell lung carcinoma. Paper presented at: 2005 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 14-18, 2005; Philadelphia, PA. Abstract #C84. Available at: http://www.aacr.org. Accessed: January 18, 2006.
21. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-3605.
22. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474-5483.
23. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-11398.
24. Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 2005; 23(16 suppl):199s (Abstract #3029).
25. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
26. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. J Clin Oncol 2005; 23(16 suppl):2s (Abstract #LBA4).